Search Within

Matthew J Matasar

  1. "Steven Horwitz"
  2. "Meeting abstract"
  3. "Andrew Zelenetz"
  4. "Radiology, Department of"
Formats
  1. Meeting Abstract (22)
Groups
  1. Center for Hematologic Malignancies (22)
  2. Department of Medicine (22)
  3. Hematologic Malignancies, Division of (22)
  4. Lymphoma (22)
  5. Population Sciences Research Program (22)
  6. Radiology, Department of (22)

More Groups

People
  1. Andrew Zelenetz (22)
  2. Steven Horwitz (22)
  3. Alison Moskowitz (20)
  4. Paul Hamlin (20)
  5. Ariela Noy (19)
  6. David Straus (19)

More People

Years
  1. 2022 (2)
  2. 2021 (3)
  3. 2020 (3)
  4. 2019 (4)
  5. 2017 (5)
  6. 2016 (2)

More Years

Publications
  1. Blood (14)
  2. Hematological Oncology (3)
  3. Journal of Clinical Oncology (3)
  4. Annals of Oncology (1)
  5. Haematologica (1)
Publishers
  1. American Society of Hematology (14)
  2. American Society of Clinical Oncology (3)
  3. Wiley Blackwell (3)
  4. Ferrata Storti Foundation (1)
  5. Oxford University Press (1)

Results (22)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2
    Meeting Abstract

    Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience
    Meeting Abstract

    Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and the role of observation in early‐stage follicular lymphoma
    Meeting Abstract

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Kumar, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Impact of interim PET on Hodgkin lymphoma treatment outcome and survival in clinical practice
    Meeting Abstract

    Zheng, S.; Gupta, K.; Goyal, P.; Nakajima, R.; Michaud, L.; Batlevi, C. L.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S. A.; Ames, A.; Biggar, E.; Moskowitz, A. J.; Batlevi, C. L.; Caron, P.; Hamilton, A. M.; Moskowitz, C. H.; Matasar, M. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Retrospective analysis of gemcitabine and oxaliplatin (GemOx)-based treatment in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Meeting Abstract

    Schade, J. R.; Kim, C.; Drill, E.; Qiu, A.; Batlevi, C. L.; Caron, P.; Colbourn, D. S.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term follow-up confirms durability of single-agent brentuximab vedotin as pre-transplant salvage for classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Schoder, H.; Lee, J.; Davey, T.; Hancock, H.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; Noy, A.; more...
    Blood (2019)

    Fulltext@MSK | Save